Want to see LTRN full AI Analyst Report?
LTRN Stock Chart & Stats
$3.02
$0.04(1.09%)
At close: 4:00 PM EST
$3.02
$0.04(1.09%)
Day’s Range― - ―
52-Week Range$1.11 - $5.74
Previous CloseN/A
Volume32.66K
Average Volume (3M)197.47K
Market Cap
$42.74M
Enterprise Value$44.77M
Total Cash (Recent Filing)$6.32M
Total Debt (Recent Filing)$59.08K
Price to Earnings (P/E)―
Beta2.32
Next Earnings
Aug 12, 2026EPS Estimate
-0.38Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.45
Shares Outstanding12,758,872
10 Day Avg. Volume165,909
30 Day Avg. Volume197,471
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)5.05
Price to Sales (P/S)0.00
P/FCF Ratio-2.11
Enterprise Value/Market Cap1.05
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-11.62K
Enterprise Value/Ebitda-2.82
Forecast
1Y Price Target
$25.00Price Target Upside727.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.57
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low reported debt is a durable strength for a clinical-stage biotech: it reduces fixed financing costs, lowers bankruptcy risk, and preserves strategic optionality to raise equity or form partnerships to fund trials. This defensive capital structure supports long-term R&D flexibility.
AI Platform Spinoff PotentialIntended separation of the withZeta.ai platform creates a structural diversification away from pure drug development: standalone AI software could generate recurring, non-dilutive licensing/subscription revenue and attract different strategic partners or investors, potentially funding or de-risking the oncology pipeline over time.
Mid-stage Pipeline Progress (LP-300)Advancing LP-300 into a Phase 2 Harmonic study is a meaningful, durable de-risking step versus preclinical assets: mid-stage data can materially change partner interest, licensing prospects, and the probability of later-stage funding, improving the company's long-term commercialization pathway if results are favorable.
Bears Say
No Revenue; Persistent LossesThe company lacks commercial revenue and remains loss-making through successive periods, meaning value creation depends entirely on clinical or platform commercialization success. Persistent negative earnings constrain internal funding, increase external capital dependence, and elevate execution risk over the medium term.
Heavy Cash Burn And Negative FCFSustained negative operating and free cash flow indicate the business cannot self-fund development. This durable cash-burn trend forces serial financing rounds or partner deals, which can slow programs, create timing risk for trials, and increase the likelihood of dilution or onerous financing terms over time.
Small Scale And Financing/dilution RiskA 24-person firm relying on small equity raises and warrant-linked financings highlights structural scale and governance risks: frequent or sizeable capital raises can materially dilute shareholders, complicate cap table, and limit continuity of long clinical programs without sustained partner or commercial revenue support.
Lantern Pharma News
LTRN FAQ
What was Lantern Pharma, Inc.’s price range in the past 12 months?
Lantern Pharma, Inc. lowest stock price was $1.11 and its highest was $5.74 in the past 12 months.
What is Lantern Pharma, Inc.’s market cap?
Lantern Pharma, Inc.’s market cap is $42.74M.
When is Lantern Pharma, Inc.’s upcoming earnings report date?
Lantern Pharma, Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 31 days.
How were Lantern Pharma, Inc.’s earnings last quarter?
Lantern Pharma, Inc. released its earnings results on May 15, 2026. The company reported -$0.3 earnings per share for the quarter, beating the consensus estimate of -$0.36 by $0.06.
Is Lantern Pharma, Inc. overvalued?
According to Wall Street analysts Lantern Pharma, Inc.’s price is currently Undervalued.
Does Lantern Pharma, Inc. pay dividends?
Lantern Pharma, Inc. does not currently pay dividends.
What is Lantern Pharma, Inc.’s EPS estimate?
Lantern Pharma, Inc.’s EPS estimate is -0.38.
How many shares outstanding does Lantern Pharma, Inc. have?
Lantern Pharma, Inc. has 12,758,872 shares outstanding.
What happened to Lantern Pharma, Inc.’s price movement after its last earnings report?
Lantern Pharma, Inc. reported an EPS of -$0.3 in its last earnings report, beating expectations of -$0.36. Following the earnings report the stock price went down -4.459%.
Which hedge fund is a major shareholder of Lantern Pharma, Inc.?
Currently, no hedge funds are holding shares in LTRN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lantern Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$25.00 (727.81% Upside)
$25.00 (727.81% Upside)
Hedge Fund Trend
Decreased
By 10.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $200.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.5%
Last 30 Days ▲ 4.1%
Last 30 Days ▲ 4.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-1.17%
12-Months-Change
Fundamentals
Return on Equity
-0.97%
Trailing 12-Months
Asset Growth
-65.76%
Trailing 12-Months
Company Description
Lantern Pharma, Inc.
Lantern Pharma Inc. is a clinical-stage biotechnology firm dedicated to revolutionizing drug development through the strategic application of artificial intelligence, machine learning, and comprehensive genomic data analysis. Their primary drug candidate, LP-100, is currently undergoing Phase II clinical trials, targeting metastatic, castration-resistant prostate cancer. The company is also advancing LP-300 as a potential combination therapy for non-small cell lung cancer adenocarcinoma, specifically in individuals who are non-smokers or have never smoked. Furthermore, their preclinical pipeline includes LP-184, an alkylating agent engineered to inflict DNA damage upon cancer cells that either overexpress specific biomarkers or exhibit mutations within their DNA repair pathways. Beyond these, Lantern Pharma maintains an antibody-drug conjugate (ADC) program for diverse cancer treatments. Central to their operations is the RADR artificial intelligence platform, which synergizes molecular data through advanced big data analytics and machine learning capabilities. Established in 2013, the company operates from its headquarters in Dallas, Texas.
LTRN Company Deck
LTRN Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant achievements in clinical trial results and regulatory progress, along with advancements in AI platform commercialization. Financial stability was noted, but there is a requirement for additional funding in the near future.View all LTRN earnings summariesLTRN Stock 12 Month Forecast
Average Price Target
$25.00
▲(727.81% Upside)
Technical Analysis
Ownership Overview
1.12% Insiders
3.30% Mutual Funds
9.54% Other Institutional Investors
83.23% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---